Novo Nordisk - Regulatory Approval (December 2025): FDA approved the first oral GLP-1 for weight loss-Novo Nordisk's once-daily semaglutide pill-which launched in January 2026 [3]

For patients using GLP-1 medications like semaglutide, we typically recommend a progressive approach to exercise that emphasizes: Resistance training 2-3 times weekly to preserve and build metabolically active muscle tissue Zone 2 cardiovascular training utilizing Miami Beachs boardwalk and beach paths for low-intensity, sustained activity Interval protocols adjusted to medication timing to optimize fat utilization Recovery strategies specific to Floridas climate, including proper hydration and timing of outdoor activities Mobility work to ensure joint health and functional capacity throughout weight loss Unlike conventional exercise prescriptions that often adopt a more is better approach, our protocols are meticulously calibrated to work synergistically with medical interventions, preventing the compensatory metabolic adaptations that can undermine progress
Last week BPI Labs, another large 503B outsourcing facility also stopped GLP-1 production
For non-diabetics struggling with obesity or being overweight, Wegovy holds promise as a treatment when used in conjunction with a reduced-calorie diet and increased physical activity
So the concept of what the body sees and doesn't sees and going back to that time question about problematic situations now versus the future
For standard oral B12 tablets or capsules, taking them with or without food generally makes little difference to absorption in individuals with normal gastrointestinal function